{"entity":{"id":"theolytics","kind":"company","name":"Theolytics","aka":["Theolytics Ltd"],"tldr":"Theolytics is an Oxford biotech that screens huge libraries of adenoviruses to find ones that kill particular cancers; THEO-260 is its lead for ovarian cancer.","summary":"Theolytics, spun out of the University of Oxford, uses directed evolution and high-throughput screening of adenovirus libraries to select oncolytic viruses with the best tumour selectivity and potency for a chosen cancer. THEO-260, selected against ovarian cancer cells, entered a phase 1/2 trial in platinum-resistant ovarian cancer in 2024 and is also being developed for intravenous delivery.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.theolytics.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["theo-260"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Oxford","country":"GB","companyType":"biotech","website":"https://www.theolytics.com/","investors":[],"funding":[]},"route":"/companies/theolytics/","neighbours":{"drug":[{"id":"theo-260","kind":"drug","name":"THEO-260","route":"/drugs/theo-260/"}]}}